Diplomat’s President Elected as Board Chair for American Foundation for Pharmaceutical Education
FLINT, Mich. – January 13, 2016 – The nation’s largest independent specialty pharmacy is proud to announce that Diplomat’s president, Gary Kadlec, has been elected as board for the American Foundation for Pharmaceutical Education.
Diplomat Pharmacy, Inc. (NYSE: DPLO) announced today that Gary Kadlec, Diplomat president, has been elected as the Chairman of the Board for the American Foundation for Pharmaceutical Education (AFPE).
The AFPE operates as an independent foundation to support pharmaceutical education in the United States. With the support of individuals and corporate contributors, AFPE supports graduate education, training and research in such disciplines as clinical pharmaceutical science, medicinal/pharmaceutical chemistry, pharmacology/toxicology, pharmaceutics, pharmacoeconomics, pharmacognosy, pharmacokinetics/metabolism, pharmacotherapy and experimental therapeutics, and social and administrative pharmacy.
The AFPE encourages exceptional students to pursue careers in the pharmaceutical sciences by funding awards to first-year graduate school and pre-doctoral fellowships in the pharmaceutical sciences, pre-doctoral fellowships in the clinical pharmaceutical sciences, and pharmacy faculty development research grants.
AFPE also enables full-time PharmD and PhD pharmacy college faculty members to undertake a minimum six-month intensive project, including coursework, training and/or research on a cutting-edge topic that benefits industry, pharmacy and pharmaceutical science education, and the national health. This nurturing of outstanding pharmacy faculty researchers advances pharmaceutical science knowledge, advances drug discovery and development, and advances the development of state-of-the-science pharmacy and pharmaceutical sciences curricula.
“I have been extremely impressed with the vision and leadership of AFPE,” said Kadlec. “I am extremely honored to have the opportunity to serve as the Chairman of Board and help us continue to make great strides in the future.”
Gary has served as president of Diplomat Pharmacy, Inc. since June 2012, and as a director of Diplomat since February 2013; he is also a member of its Nominating and Corporate Governance Committee. From 2004 through 2007, he was the chief operating officer, and from 2007 to 2011, the chief executive officer and president, of excelleRx, an Omnicare company based in Philadelphia, Pennsylvania, specializing in medication therapy management. Prior to his time at excelleRx, Gary served as president of Specialized Pharmacy Services in Livonia, Michigan, from 1976 until it was acquired by Omnicare, Inc. in 1995. He then served as Regional and then Senior Regional Vice President of Omnicare until 2004.
To learn more about Diplomat, visit www.diplomat.is.
This press release contains forward-looking statements made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. Forward-looking statements give current expectations or forecasts of future events or our future financial or operating performance. The forward-looking statements contained in this press release are based on management’s good-faith belief and reasonable judgment based on current information. These statements are qualified by important risks and uncertainties, many of which are beyond our control, that could cause our actual results to differ materially from those forecasted or indicated by such forward-looking statements. For a discussion of such risks and uncertainties, you should review Diplomat’s filings with the Securities and Exchange Commission, including “Risk Factors” in Diplomat’s Annual Report on Form 10-K for the year ended December 31, 2014 and in subsequent reports filed with or furnished to the Securities and Exchange Commission. Except as may be required by any applicable laws, Diplomat assumes no obligation to publicly update such forward-looking statements, which are made as of the date hereof or the earlier date specified herein, whether as a result of new information, future developments or otherwise.
Diplomat (NYSE: DPLO) serves patients and physicians in all 50 states. Headquartered in Flint, Michigan, the company focuses on medication management programs for people with complex chronic diseases, including oncology, immunology, hepatitis, multiple sclerosis, HIV, specialized infusion therapy and many other serious or long-term conditions. Diplomat opened its doors in 1975 as a neighborhood pharmacy with one essential tenet: “Take good care of patients, and the rest falls into place.” Today, that tradition continues—always focused on improving patient care and clinical adherence. For more information visit www.diplomat.is. Follow us on Twitter and LinkedIn and like us on Facebook.
Kali Lucas, Public Relations Coordinator
810.768.9580 | firstname.lastname@example.org
@PharmacDailyRT @PharmacDaily: @DiplomatRx to distribute Puma Biotechnology’s new cancer drug $DPLO https://t.co/gl0v6WURVV4 days ago
@DiplomatRxNerlynx (neratinib) tablets for HER2+ Breast Cancer in the Extended Adjuvant Setting https://t.co/vi3ACWhbfe5 days ago
@AJPB_JournalRT @AJPB_Journal: Be sure to check out our Insights page featuring videos of Cheryl Allen from @DiplomatRx discussing #RA https://t.co/qxZc…2 weeks ago
@DiplomatRxWe're with @340BCoalition this week in Washington D.C.! Come say hello.2 weeks ago
@SpecialtyPTimesRT @SpecialtyPTimes: Rheumatoid Arthritis Treatment Guidelines https://t.co/sEhe74UozC #rheumatoidarthritis @DiplomatRx3 weeks ago